Completed PHASE4 INTERVENTIONAL 1-arm NCT02953730

The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents

The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents

Sponsor: Chinese Academy of Medical Sciences

Conditions Acute Lymphoid Leukemia

Interventions PEG-rhG-CSF

Updated 6 times since 2017 Last updated: Nov 1, 2016 Started: Sep 30, 2015 Primary completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02953730, this PHASE4 trial focuses on Acute Lymphoid Leukemia and remains completed. Sponsored by Chinese Academy of Medical Sciences, it has been updated 6 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Oct 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Medical Sciences

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China